Biblio

Found 26 results
Author Keyword [ Title(Desc)] Type Year
Filters: Author is Gordon J S Rustin  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
J. A. Ledermann, Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., Friedlander, M. Leonard, Gonzalez-Martin, A., Stark, D., Clark, E., Farrelly, L., Swart, A. Marie, Cook, A. D., Kaplan, R. S., and Parmar, M. K. B., Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet, vol. 387, no. 10023, pp. 1066-74, 2016.
J. B. Vermorken, Parmar, M. K. B., Brady, M. F., Eisenhauer, E., Högberg, T., Ozols, R. F., Rochon, J., Rustin, G. J. S., Sagae, S., Verheijen, R. H. M., InterGroup, G. Cancer, ,, /NCRI, M. R. C., ,, -CTG, N. C. I. C., ,, -OVAR, A. G. O., and , Clinical trials in ovarian carcinoma: study methodology, Ann Oncol, vol. 16 Suppl 8, pp. viii20-viii29, 2005.
J. B. Vermorken, Parmar, M. K. B., Brady, M. F., Eisenhauer, E., Högberg, T., Ozols, R. F., Rochon, J., Rustin, G. J. S., Sagae, S., and Verheijen, R. H. M., Clinical trials in ovarian carcinoma: study methodology., Ann Oncol, vol. 16 Suppl 8, pp. viii20-viii29, 2005.
G. J. S. Rustin, Timmers, P., Nelstrop, A., Shreeves, G., Bentzen, S. M., Baron, B., Piccart, M. J., Bertelsen, K., Stuart, G. C. E., Cassidy, J., and Eisenhauer, E., Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide., J Clin Oncol, vol. 24, no. 1, pp. 45-51, 2006.
R
R. M. Glasspool, Brown, R., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R. H., Pledge, S., Paul, J., Mackean, M., Hall, G. D., Gabra, H., Halford, S. E., Walker, J. L., Appleton, K., Ullah, R., Kaye, S. B., and Group, S. Gynaecolog, A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer, Br J Cancer, vol. 110, pp. 1923-9, 2014.
M. E. Gore, Oza, A. M., Rustin, G. J. S., Malfetano, J. H., Calvert, A. H., Clarke-Pearson, D. L., Carmichael, J., Ross, G., Beckman, R. A., and Fields, S. Z., A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer., Eur J Cancer, vol. 38, no. 1, pp. 57-63, 2002.
I. B. Vergote, Rustin, G. J. S., Eisenhauer, E., Kristensen, G. B., Pujade-Lauraine, E., Parmar, M. K. B., Friedlander, M. Leonard, Jakobsen, A., and Vermorken, J. B., Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup., J Natl Cancer Inst, vol. 92, no. 18, pp. 1534-5, 2000.
G. J. S. Rustin, Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., Greven, K., Vergote, I. B., Cervantes, A., and Vermorken, J. B., Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)., J Natl Cancer Inst, vol. 96, no. 6, pp. 487-8, 2004.
J. A. Ledermann, Marth, C., Carey, M. S., Birrer, M. J., Bowtell, D. D. L., Kaye, S. B., McNeish, I., Oza, A. M., Scambia, G., Rustin, G. J. S., Stehman, F. B., Gershenson, D., Thomas, G., Berns, E. M. J. J., Casado, A., Ottevanger, N., Hilpert, F., Kim, B. - G., Okamoto, A., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer., Int J Gynecol Cancer, vol. 21, no. 4, pp. 763-70, 2011.
S
P. A. Vasey, Atkinson, R. J., Osborne, R., Parkin, D., Symonds, R., Paul, J., Lewsley, L. A., Coleman, R. L., Reed, N. Simon, Kaye, S. B., and Rustin, G. J. S., SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer, Br J Cancer, vol. 94, pp. 62-8, 2006.
M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard, Small cell of the ovary, hypercalcemic type – analysis of combined experience and recommendation for management. A GCIG study, Gynecol Oncol, vol. 100, pp. 233-8, 2006.
M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard, Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study., Gynecol Oncol, vol. 100, no. 2, pp. 233-8, 2006.
A. M. Oza, Cook, A. D., Pfisterer, J., Embleton, A. C., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G. B., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T. - W., Rustin, G. J. S., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A. M., Jayson, G. C., Stark, D., Swart, A. Marie, Farrelly, L., Kaplan, R. S., Parmar, M. K. B., and Perren, T. J., Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial., Lancet Oncol, vol. 16, no. 8, p. 936, 2015.

Pages